
FDA committee rejects two IQOS MRTP claims, approves one
25th January 2018 - News analysis |
Agency’s science committee agrees that PMI product decreases exposure to dangerous chemicals, but won’t accept broader claims of long-term risk reduction
Agency’s science committee agrees that PMI product decreases exposure to dangerous chemicals, but won’t accept broader claims of long-term risk reduction
Submit your access request to explore how it streamlines access to critical market and regulatory insights
"*" indicates required fields